GAN & LEE PHARMACEUTICALS. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.03 CNY | -1.54% |
|
+1.98% | -3.08% |
ETFs positioned on Gan & Lee Pharmaceuticals.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 35 M€ | -5.85% | - | |
| 0.00% | 0 M€ | +3.53% | - |
Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.
Sector
Pharmaceuticals
Calendar
16/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
51.03
CNY
Average target price
62.5
CNY
Spread / Average Target
+22.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.08% | 4.17B | |
| -2.35% | 89.33B | |
| +3.29% | 41.19B | |
| -15.40% | 31.87B | |
| +53.42% | 24.52B | |
| -14.35% | 15.68B | |
| -39.65% | 12.23B | |
| -6.52% | 12.34B | |
| -13.41% | 12.21B | |
| +6.22% | 8.83B |
- Stock Market
- Equities
- 603087 Stock
- Funds and ETFs Gan & Lee Pharmaceuticals.
